# Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

> **NCT00125190** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 45 (actual)

## Conditions studied

- Insulin-Like Growth Factor-1 Deficiency
- Growth Disorders

## Interventions

- **DRUG:** rhIGF-1 (mecasermin) for a period of 86 weeks

## Key facts

- **NCT ID:** NCT00125190
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125190, "Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00125190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*